Innovaxis achieves CDTI financing thanks to its innovative and competitive character

The R&D project, which is being developed by Innovaxis focuses on the development of new stem cell medicine, obtained funding from the Centre for Technological Development (CDTI) Innovaxis obtains financing through Innplanta 2012 Program

The biopharmaceutical company Innovaxis specialises in the R&D and in the commercialisation of advanced cell therapies.

+34 956 549 169

This proyect has been financed with €191,738 by INNPLANTA 2012, through the Spanish Ministry of Economy and Competitiveness, inside the “Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica 2008-2011” (Project number INP-2012-0166-PCT-300000-ACT1) cofinanced by the European Regional Development Fund (FEDER), “Una manera de hacer Europa”)

This proyect has been funded by INNPLANTA 2011, through the Spanish Ministry of Economy and Competitiveness, co-funded by FEDER funds of the EU, “Una manera de hacer Europa”


Innovaxis is a biopharmaceutical company which produces cellular medicines and stem cells advance therapies

A stem cell is a cell that has the potential to self-renew by cell division and differentiate into specialised cells. The two classical properties of a stem cell are its self-renewal and potency. Self-renewal is the ability for the cell to pass through numerous cycles of cell division while maintaining an undifferentiated state. Innovaxis has a state-of-the-art technological platform which allows treatment of the peripheral vascular disease (PVD).

Diabetic Associated PVD is a nearly pandemic condition that has the potential to cause loss of a limb or even loss of life. Peripheral vascular disease manifests as insufficient tissue perfusion caused by existing atherosclerosis that may be acutely compounded by either emboli or thrombi, or diabetes. Many people live daily with peripheral vascular disease; however, in settings such as chronic limb ischemia, this pandemic disease can be life threatening and can require emergency intervention.

ATMPs (Advanced Therapies Medicinal Products) are innovative, regenerative therapy-based medicines which combine aspects of medicine, cell biology, science and engineering for the purpose of regenerating, repairing or replacing damaged tissues or cells.

In the last few decades, science and medicine have experienced many significant advances, which have resulted in improved healthcare and life quality, as well as extended life span in developed countries.

Stem cells are characterised by two unique properties: on one hand, they can replicate themselves, hence becoming virtually immortal. On the other hand, they can differentiate into many cell types, hence regenerating the body cells.


Copyright 2013 Innovaxis. All Rights Reserved
Legal Advice